|
Dr. Treves is a leading Israeli expert on HSC who has published more than 80 scientific publications and holds ten patents and has successfully obtained FDA approval for clinical trials of an HSC product. He received his Ph.D. at the Weizmann Institute of Science and is currently Executive Deputy of Israel’s Sheba Cancer Research Center. He is directed many industry and academic R&D programs in stem cell therapy immunology hematology and oncology.
Dr. Treves was the founder President and CEO of Gamida-Cell Ltd. an Israeli biotechnology company working in the field of HSC expansion and was instrumental in obtaining FDA approval for clinical trials of stem cell biopharmaceutical product. He has substantial experience in regulatory affairs for biologicals and cell therapy in clinical trials and in manufacture of cell products under GMP. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. | 